K filing with the Securities and Exchange Commission (SEC) that the company has established a Collaboration and License Agreement with Nippon Shinyaku Co., Ltd. This collaboration focuses on the ...

REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Regenxbio Inc (RGNX) stock saw a modest uptick, ending the day at $7.05 which represents a slight increase of $0.10 or 1.44% from the prior close of $6.95. The stock opened at $7.17 and touched a low ...

Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and ...

Plus: Rockville gene therapy company inks deal; Pioneering politician from Montgomery County celebrated with portrait ...

Shares of US biotech Regenxbio surged 18.4% in pre-open trading Tuesday after announced a strategic partnership with Japan’s ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along ...

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $36.00.Stay ...

Rockville, Maryland Wednesday, January 15, 2025, 12:00 Hrs [IST] ...

REGENXBIO (NASDAQ:RGNX) and Nippon Shinyaku have entered into a partnership for the development and commercialization of REGENXBIO's gene therapies RGX-121 for the treatment of Hunter syndrome, or MPS ...

III study in treating thyroid eye disease. The privately held company posted top-line efficacy and safety results from a phase IIb/III study of its lead candidate, linsitinib, which hits its primary ...